Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1881. Islet cell transplantation for the treatment of type 1 diabetes

Islet cell transplantation for the treatment of type 1 diabetes Islet cell transplantation for the treatment of type 1 diabetes Islet cell transplantation for the treatment of type 1 diabetes Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Islet cell transplantation for the treatment of type 1 diabetes. Lansdale: HAYES, Inc.. Directory Publication. 2004 Authors (...) ' objectives Islet cell transplantation is performed in patients with type 1 (insulin-dependent) diabetes mellitus, with the goals of eliminating the need for exogenous insulin and improving glucose control, thereby preventing or reversing secondary diabetic complications, such as retinopathy, neuropathy, nephropathy, and vasculopathy. Project page URL Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 1; Islets

2004 Health Technology Assessment (HTA) Database.

1882. Closing the quality gap: a critical analysis of quality improvement strategies, volume 2 - diabetes mellitus care

of the more than 17 million patients in the United States with diabetes. This review examines strategies for improving the quality of care for adult type 2 diabetic patients, through changes in provider behavior and modifications to the organization of care. Authors' conclusions The authors' analysis of quality improvement strategies for diabetes care showed no particular type of QI to have an advantage over others, but suggested that employing at least two strategies provides a greater chance of success (...) Closing the quality gap: a critical analysis of quality improvement strategies, volume 2 - diabetes mellitus care Closing the quality gap: a critical analysis of quality improvement strategies, volume 2 - diabetes mellitus care Closing the quality gap: a critical analysis of quality improvement strategies, volume 2 - diabetes mellitus care Shojania KG, Ranji SR, Shaw LK, Charo LN, Lai JC, Rushakoff RJ, McDonald KM, Owens DK Record Status This is a bibliographic record of a published health

2004 Health Technology Assessment (HTA) Database.

1883. Insulin glargine for type 2 diabetes

Insulin glargine for type 2 diabetes Insulin glargine for type 2 diabetes Insulin glargine for type 2 diabetes Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office for Health Technology Assessment. Insulin glargine for type 2 diabetes. Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of insulin glargine (Trade Mark: Lantus) - a biosynthetic, long-acting human insulin analogue - to treat type 2 diabetes. Authors' conclusions Patients who have adequate glycemic control and minimal hypoglycemic events with NPH insulin will likely not derive additional benefit from insulin glargine (in most studies, insulin glargine did not significantly reduce fasting

2004 Health Technology Assessment (HTA) Database.

1884. Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes

Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Cote B, St-Hilaire C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Cote B, St-Hilaire C. Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 04-07. 2004 Authors' objectives This report examines the safety, efficacy and cost-effectiveness of the insulin pump compared to multiple daily insulin injections for the treatment of type 1 diabetes, a chronic

2004 Health Technology Assessment (HTA) Database.

1885. Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus

Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus Dretzke J, Cummins C, Sandercock J, Fry-Smith A, Barrett T, Burls A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Dretzke J, Cummins C, Sandercock J, Fry-Smith A, Barrett T, Burls A. Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus. Health Technology Assessment 2004; 8(22): 1-196 Authors' objectives The aim of this review was to determine the role of autoantibody tests for autoimmune diseases in children with newly diagnosed type 1 diabetes mellitus. Authors' conclusions In terms of test accuracy in testing for coeliac disease, IgA EMA (using indirect

2004 Health Technology Assessment (HTA) Database.

1886. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation Czoski-Murray C (...) , Warren E, Chilcott J, Beverley C, Psyllaki M A, Cowan J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki M A, Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health

2004 Health Technology Assessment (HTA) Database.

1887. Type 2 diabetes: Prevention and management of foot problems

Type 2 diabetes: Prevention and management of foot problems Type 2 diabetes: Prevention and management of foot problems Type 2 diabetes: Prevention and management of foot problems National Institute for Clinical Excellence Citation National Institute for Clinical Excellence. Type 2 diabetes: Prevention and management of foot problems. London: National Institute for Clinical Excellence (NICE) 2004: 27 Authors' objectives

This report provides guidelines on the prevention and management of foot (...) problems in type 2 diabetes.

Authors' conclusions Key priorities for implementation General management approach - Effective care involves a partnership between patients and professionals, and all decision making should be shared. - Arrange recall and annual review as part of ongoing care. - As part of annual review, trained personnel should examine patients' feet to detect risk factors for ulceration. - Examination of patients feet should include: - testing of foot sensation using a 10 g

2004 Health Technology Assessment (HTA) Database.

1888. Islet transplantation in patients with type 1 diabetes mellitus

Islet transplantation in patients with type 1 diabetes mellitus Islet transplantation in patients with type 1 diabetes mellitus Islet transplantation in patients with type 1 diabetes mellitus Piper M, Seidenfeld J, Aronson N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Piper M, Seidenfeld J, Aronson N. Islet transplantation in patients (...) with type 1 diabetes mellitus. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 98. 2004 Authors' objectives This report aims to provide a systematic evidence review on the outcomes of islet transplantation, particularly using the Edmonton or a subsequently developed islet transplant protocol. Authors' conclusions Evidence on outcomes of islet transplant is limited by small patient numbers, short followup, and lack of standardized reporting

2004 Health Technology Assessment (HTA) Database.

1889. Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults

Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults. London: National Institute for Clinical Excellence (NICE) 2004: 112 Authors' objectives This report provides guidelines on the diagnosis and management of type 1 diabetes in children, young people and adults. Authors' conclusions Key priorities for implementation: children and young people Management from diagnosis: Children and young

2004 Health Technology Assessment (HTA) Database.

1890. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis

. 2004 Authors' objectives To assess the effect of omega-3 fatty acids on 1) total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and insulin resistance in type-II diabetes and the metabolic syndrome, 2) clinical score, sigmoidoscopic score, histologic score and requirement for immunosuppressive therapy in inflammatory bowel disease (IBD), 3) pain, swollen and tender joint counts, acute phase reactants, patient global assessment, and requirement for anti-inflammatory (...) type II diabetics. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Fatty Acids, Omega-3; Inflammatory Bowel Diseases; Kidney Diseases; Lupus Erythematosus, Systemic; Metabolic Syndrome X; Osteoporosis Language Published English Country of organisation United States Address for correspondence Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1

2004 Health Technology Assessment (HTA) Database.

1891. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. (Abstract)

European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Results of studies in animals and human beings suggest that type 1 diabetes is preventable. Nicotinamide prevents autoimmune diabetes in animal models, possibly through inhibition of the DNA repair enzyme poly-ADP-ribose polymerase and prevention of beta-cell NAD depletion. We aimed to assess whether high dose nicotinamide prevents or delays clinical (...) onset of diabetes in people with a first-degree family history of type 1 diabetes.We did a randomised double-blind placebo-controlled trial of nicotinamide in 552 relatives with confirmed islet cell antibody (ICA) levels of 20 Juvenile Diabetes Federation (JDF) units or more, and a non-diabetic oral glucose tolerance test. Participants were recruited from 18 European countries, Canada, and the USA, and were randomly allocated oral modified release nicotinamide (1.2 g/m2) or placebo for 5 years

2004 Lancet Controlled trial quality: predicted high

1892. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. Full Text available with Trip Pro

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. Few studies have directly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-converting-enzyme (ACE) inhibitors in persons with type 2 diabetes.In this prospective, multicenter, double-blind, five-year study, we randomly assigned 250 subjects with type 2 diabetes and early nephropathy to receive either the angiotensin II-receptor blocker telmisartan (80 mg (...) interval, in favor of enalapril, was greater than the predefined margin of -10.0 ml per minute per 1.73 m2, indicating that telmisartan was not inferior to enalapril. The effects of the two agents on the secondary end points were not significantly different after five years.Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes. These findings do not necessarily apply to persons with more advanced nephropathy, but they support the clinical

2004 NEJM Controlled trial quality: predicted high

1893. Preventing microalbuminuria in type 2 diabetes. Full Text available with Trip Pro

Preventing microalbuminuria in type 2 diabetes. The multicenter double-blind, randomized Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting-enzyme inhibitors and non-dihydropyridine calcium-channel blockers, alone or in combination, prevent microalbuminuria in subjects with hypertension, type 2 diabetes mellitus, and normal urinary albumin excretion.We studied 1204 subjects, who were randomly assigned to receive at least three years (...) trandolapril and placebo (P=0.01), and 0.83 for the comparison between verapamil and placebo (P=0.54). Trandolapril plus verapamil and trandolapril alone delayed the onset of microalbuminuria by factors of 2.6 and 2.1, respectively. Serious adverse events were similar in all treatment groups.In subjects with type 2 diabetes and hypertension but with normoalbuminuria, the use of trandolapril plus verapamil and trandolapril alone decreased the incidence of microalbuminuria to a similar extent. The effect

2004 NEJM Controlled trial quality: predicted high

1894. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Full Text available with Trip Pro

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers.To compare the effects of beta-blockers with different pharmacological profiles on glycemic and metabolic control in participants with DM (...) and hypertension receiving renin-angiotensin system (RAS) blockade, in the context of cardiovascular risk factors.A randomized, double-blind, parallel-group trial (The Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives [GEMINI]) conducted between June 1, 2001, and April 6, 2004, at 205 US sites that compared the effects of carvedilol and metoprolol tartrate on glycemic control. The 1235 participants were aged 36 to 85 years with hypertension (>130/80 mm Hg) and type 2 DM

2004 JAMA Controlled trial quality: predicted high

1895. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Full Text available with Trip Pro

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). To investigate whether a low dose of the angiotensin converting enzyme (ACE) inhibitor ramipril lowers cardiovascular and renal events in patients with type 2 diabetes who have microalbuminuria or proteinuria.Randomised, double blind, parallel group trial comparing ramipril (1.25 mg (...) /day) with placebo (on top of usual treatment) for cardiovascular and renal outcomes for at least three years.Multicentre, primary care study conducted mostly by general practitioners in 16 European and north African countries.4912 patients with type 2 diabetes aged >50 years who use oral antidiabetic drugs and have persistent microalbuminuria or proteinuria (urinary albumin excretion > or = 20 mg/l in two consecutive samples), and serum creatinine < or = 150 micromol/l.The primary outcome measure

2004 BMJ Controlled trial quality: predicted high

1896. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials Scheen A J CRD summary This review assessed the effects of renin-angiotensin system (RAS) inhibition on the development (...) of type 2 diabetes in patients with arterial hypertension or congestive heart failure. The author concluded that RAS inhibition may help prevent type 2 diabetes. Given the lack of a quality assessment and the insufficient reporting of the review methods, the reliability of the author's conclusions cannot be adequately assessed. Authors' objectives To assess the effects of renin-angiotensin system (RAS) inhibition on the incidence of new cases of type 2 diabetes mellitus (T2DM) in patients

2004 DARE.

1897. Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus

Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus Dretzke J, Cummins C, Sandercock J, Fry-Smith A, Barrett T, Burls A CRD summary This generally well-conducted review assessed the accuracy of autoantibody tests for the diagnosis of coeliac disease (not its stated objective). Limitations in the analysis mean (...) that conclusions (IgA EMA and IgA TTG were most accurate) should be interpreted cautiously; there was considerable variation in the reported sensitivity of both tests and potential sources of variation required consideration. Authors' objectives To assess the role of autoantibody testing for autoimmune disease in children with newly diagnosed type 1 diabetes mellitus. The authors presented a brief summary of the evidence on autoantibody testing for thyroid disease and a full systematic review and decision

2004 DARE.

1898. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians

Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians Vijan S, Hayward R A CRD summary This review assessed the effectiveness of pharmacologic lipid-lowering therapy in preventing (...) cardiovascular events in patients with type 2 diabetes. Lipid-lowering agents were found to reduce cardiovascular risk. However, the authors warned that recommendations for primary prevention therapy could not be made for diabetics with relatively low cardiovascular risk. The evidence was not assessed for quality, hence the conclusions may not be reliable. Authors' objectives To assess the effectiveness of pharmacologic lipid-lowering therapy in patients with type 2 diabetes mellitus. Searching MEDLINE

2004 DARE.

1899. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

1900. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes

Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.